Paul Shaw

Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial

Dean A. Fennell, Sean Ewings, Christian H. Ottensmeier et al. · The Lancet Oncology · 2021 · 259 citations · Full text

Medicine, Oncology, Pharmacology +15

Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial

Gary Middleton, Kristian Brock, Joshua Savage et al. · The Lancet Respiratory Medicine · 2020 · 169 citations · Full text

Medicine, Oncology, Pharmacology +11

Patterns and Predictors of Relapse Following Radical Chemoradiation Therapy Delivered Using Intensity Modulated Radiation Therapy With a Simultaneous Integrated Boost in Anal Squamous Cell Carcinoma

Rebecca Shakir, Richard Adams, Rachel Cooper et al. · International Journal of Radiation Oncology*Biology*Physics · 2019 · 72 citations · Full text

Medicine, Oncology, Radiation Oncology +17

CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer

Gerard Walls, Jamie B. Oughton, Anthony J. Chalmers et al. · Clinical and Translational Radiation Oncology · 2020 · 34 citations · Full text

Medicine, Oncology, Radiation Oncology +16

CHARIOT: a phase I study of berzosertib with chemoradiotherapy in oesophageal and other solid cancers using time to event continual reassessment method

Sohail Rooman Javed, Simon Lord, S. El Badri et al. · British Journal of Cancer · 2023 · 34 citations · Full text

Medicine, Oncology, Pharmacology +16